Valneva's Lyme borreliosis
vaccine candidate - VLA15
Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme borreliosis.
Pre-clinical data showed that this vaccine candidate can provide protection against the majority of Borrelia species pathogenic for humans (Source
This candidate has completed pre-clinical development and is progressing into clinical testing (Phase I) following the Investigational New Drug application (IND) clearance from the Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in Europe (Belgium).
This program is supported by the Vienna Business Agency.